Guardant Health (GH) News Today

Guardant Health, Inc. (NASDAQ:GH) saw its stock pull back after profit‐taking but also received several bullish analyst upgrades and reported strong Q2 results. Management is engaging with investors through upcoming events, balancing cautious near‐term trading with positive longer‐term outlooks.

• Positive Sentiment: Scotiabank raised its price target on Guardant Health from $57.00 to $60.00 and maintained a “sector outperform” rating. Guardant Health Price Target Raised to $60.00
• Positive Sentiment: Raymond James boosted its price target on GH from $59.00 to $61.00 and reiterated an “outperform” rating. Guardant Health Stock Price Expected to Rise, Raymond James Financial Analyst Says
• Positive Sentiment: Q2 revenue rose 31% year-over-year, reflecting continued strength in core precision oncology tests. Guardant Health (GH) Q2 Revenue Up 31%
• Positive Sentiment: Guardant Health beat Q2 expectations and provided strong full-year sales guidance, underscoring confidence in its growth trajectory. Guardant Health (NASDAQ:GH) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
• Neutral Sentiment: Guardant Health will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13th. Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
• Neutral Sentiment: Q2 2025 earnings call transcript is now available, detailing management’s commentary on performance and strategy. Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: Investors can review the Q2 earnings presentation for key metrics and upcoming catalysts. Guardant Health, Inc. 2025 Q2 - Results - Earnings Call Presentation
• Negative Sentiment: The stock traded down roughly 7.6%, reflecting short-term profit-taking and market volatility. Guardant Health (NASDAQ:GH) Trading Down 7.6% - Here's What Happened